Our data, combined with the previous ones, suggest semaforines, especially SEMA6A and SEMA7A, as a new class of biomarkers for monitoring nusinersen treatment in all SMA patients, regardless of their severity, reflecting axon maintenance and remodeling, as already emerged in other condition [53]. Here, SEMA6A is linked to proximal spinal muscular atrophy.